OSE Stock Overview
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
OSE Immunotherapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€6.93|
|52 Week High||€13.68|
|52 Week Low||€4.60|
|1 Month Change||3.13%|
|3 Month Change||0.73%|
|1 Year Change||-38.24%|
|3 Year Change||93.58%|
|5 Year Change||2.67%|
|Change since IPO||-33.68%|
Recent News & Updates
OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be
The latest analyst coverage could presage a bad day for OSE Immunotherapeutics SA ( EPA:OSE ), with the analysts making...
|OSE||FR Biotechs||FR Market|
Return vs Industry: OSE exceeded the French Biotechs industry which returned -39.4% over the past year.
Return vs Market: OSE underperformed the French Market which returned -3.7% over the past year.
|OSE Average Weekly Movement||14.2%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||5.9%|
|10% most volatile stocks in FR Market||10.0%|
|10% least volatile stocks in FR Market||3.4%|
Stable Share Price: OSE is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: OSE's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company’s products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation.
OSE Immunotherapeutics Fundamentals Summary
|OSE fundamental statistics|
Is OSE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OSE income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.91|
|Net Profit Margin||-64.05%|
How did OSE perform over the long term?See historical performance and comparison
Is OSE Immunotherapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OSE (€6.93) is trading below our estimate of fair value (€945.04)
Significantly Below Fair Value: OSE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OSE is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.
PE vs Market: OSE is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OSE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OSE's Price-To-Book Ratio (2.7x) is in line with the FR Biotechs industry average.
How is OSE Immunotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OSE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OSE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OSE's revenue (38.8% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: OSE's revenue (38.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OSE's Return on Equity is forecast to be high in 3 years time
How has OSE Immunotherapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSE is currently unprofitable.
Growing Profit Margin: OSE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OSE is unprofitable, and losses have increased over the past 5 years at a rate of 50.6% per year.
Accelerating Growth: Unable to compare OSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: OSE has a negative Return on Equity (-35.18%), as it is currently unprofitable.
How is OSE Immunotherapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OSE's short term assets (€44.2M) exceed its short term liabilities (€16.8M).
Long Term Liabilities: OSE's short term assets (€44.2M) exceed its long term liabilities (€37.2M).
Debt to Equity History and Analysis
Debt Level: OSE has more cash than its total debt.
Reducing Debt: OSE's debt to equity ratio has increased from 2.8% to 67.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OSE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OSE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is OSE Immunotherapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OSE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dominique Costantini (65 yo)
Dr. Dominique Costantini, M.D. serves as Interim Chief Executive Officer at OSE Immunotherapeutics SA since January 17, 2022. She Co-founded OSE Pharma SA in 2012 and serves as its Chief Executive Officer....
CEO Compensation Analysis
Compensation vs Market: Dominique's total compensation ($USD441.16K) is above average for companies of similar size in the French market ($USD285.89K).
Compensation vs Earnings: Dominique's compensation has increased whilst the company is unprofitable.
Experienced Management: OSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: OSE's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
OSE Immunotherapeutics SA's employee growth, exchange listings and data sources
- Name: OSE Immunotherapeutics SA
- Ticker: OSE
- Exchange: ENXTPA
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €128.218m
- Shares outstanding: 18.50m
- Website: https://www.ose-immuno.com
Number of Employees
- OSE Immunotherapeutics SA
- 22, boulevard Benoni Goullin
- Pays de la Loire
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/28 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.